About US
Contact us
-
Merck to pay up to $37M in Canadian Vioxx caseMerck ($MRK) is wrapping up a Canadian class action suit by pledging to pay up to $37 million to Vioxx patients who developed heart problems after using the drug. The settlement includes $10 milli2012/1/20
-
Can AstraZeneca continue to swear off major M&A?Can AstraZeneca ($AZN) CEO David Brennan stick to his no-megadeals diet? Analysts are beginning to wonder, says Bloomberg, now that three of the company's promising drug candidates have stumbled. Th2012/1/20
-
Pharma gets its close-up in new Hollywood filmsPharma films are all the rage in Hollywood these days--and several more are on the horizon. After "Love and Other Drugs" turned Jake Gyllenhaal into a Viagra rep and "Contagion" made a vaccine res2012/1/19
-
UPDATED: J&J said to settle TX Risperdal case for $158MJohnson & Johnson ($JNJ) says it will pay $158 million to settle a high-profile Texas suit alleging that it defrauded the state by misleading doctors about its antipsychotic drug Risperdal. Bloo2012/1/19
-
Novartis hammers out deal to keep Nyon plant openDon't accuse Novartis ($NVS)CEO Joe Jimenez (photo) of refusing to listen. After workers in Nyon, Switzerland, stopped work to protest their plant's closure, the company sat down to talk about oth2012/1/18
-
Generics market to bulk up by $100B in 5 yearsWith leading generics makers moving into branded drugs as a hedge against slowing growth of the copycat industry, one might think the knockoff-drug business has transfigured into a tortoise, or pe2012/1/18
-
Bit by bit, Lundbeck trims fat from production costsOutsourcing to cut costs? Shipping work to China? No need, says Lundbeck. The Danish drugmaker has slashed its own manufacturing costs25% over the past 5 years, the Financial Times reports, saving2012/1/18
-
J&J whistleblower testifies in TX Risperdal caseAs the Risperdal marketing trial grinds on in Texas, a whistleblower took the stand to testify he was fired for raising questions. Allen Jones, who leveled allegations of mismarketing against Johnso2012/1/17
-
Numbers hint that Pfizer's Lipitor strategy may workThe latest figures on Lipitor sales suggest that Pfizer's ($PFE) aggressive sales strategies might—just might—be working. As The Associated Press reports, new IMS Health numbers show sales plateauin2012/1/17
-
Nestle Said to Vie With Danone to Buy Pfizer Baby-Food UnitNestle SA (NESN) and Danone SA (BN) made first- round bids for Pfizer Inc. (PFE)’s baby-formula unit, putting two of Europe’s largest food companies in competition for the division, people with knowle2012/1/16